Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Giang Vu

Physician Assistant, Medical Tacoma, WA Physician Assistant

NPI 1386733483 CMS profile 11022013

11225 Pacific Ave S, Tacoma, WA 98444

Open in the dashboard

General payments

$8,862

423 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Giang Vu of Tacoma, WA is reported in the CMS Open Payments database as having received $8,862 across 423 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,282 151
2024 General $2,457 120
2023 General $1,533 72
2022 General $994 46
2021 General $596 34

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Giang Vu
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Giang Vu were reported at $3,282. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Giang Vu Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $596 $156 $41–$563 $132
2022 $994 $185 $55–$649 $149
2023 $1,533 $199 $58–$717 $160
2024 $2,457 $206 $62–$740 $164
2025 $3,282 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,278 144 payments
  2. Axsome Therapeutics, Inc. $701 36 payments
  3. Jazz Pharmaceuticals Inc. $640 19 payments
  4. Lilly USA, LLC $619 27 payments
  5. Novo Nordisk Inc $577 26 payments
  6. Lundbeck LLC $414 29 payments
  7. Janssen Pharmaceuticals, Inc $373 10 payments
  8. Otsuka America Pharmaceutical, Inc. $299 12 payments
  9. Corcept Therapeutics $257 11 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $239 9 payments
  11. Other $2,464 100 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,582 420 payments
  2. Education $280 3 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $907 51 payments
  2. QULIPTA $802 45 payments
  3. Sunosi $666 35 payments
  4. VRAYLAR Neuroscience $535 38 payments
  5. VRAYLAR Neuroscience $458 28 payments
  6. REXULTI $414 29 payments
  7. Ozempic $389 15 payments
  8. SPRAVATO $373 10 payments
  9. MOUNJARO $351 14 payments
  10. XYWAV $337 15 payments
  11. Other $5,058 215 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

1,513

Median for Physician Assistant: 241

Drug cost

$131,049

Median for Physician Assistant: $4,110

Branded share of claims

24.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Syringe Dupilumab Brand 12 $48,066
Jardiance Empagliflozin Brand 25 $22,900
Eliquis Apixaban Brand 19 $14,616
Ozempic Semaglutide Brand 13 $12,409
Trulicity Dulaglutide Brand 12 $11,026
Advair Diskus Fluticasone Propion/Salmeterol Brand 12 $3,283
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 13 $1,913
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 34 $1,746
Synthroid Levothyroxine Sodium Brand 11 $1,295
Duloxetine Hcl Generic 35 $1,085

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$31,304

Medicare's payments for the services billed

Medicare patients

164

Average age 74

Services billed

612

72 women, 92 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Diabetes 34%
Ischemic heart disease 25%
Atrial fibrillation 20%
COPD 20%
Depression 20%
Heart failure 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 27 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $361
$361 — —
REXULTI
  • Lundbeck LLC $214
  • Otsuka America Pharmaceutical, Inc. $73
$287 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $151
$151 — —
Sunosi
  • Axsome Therapeutics, Inc. $139
$139 — —
UBRELVY
  • AbbVie, Inc. $124
$124 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 27 with Patron

Records

423 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record